TÜBINGEN, Germany and BOSTON, June 12, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully-integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the appointment of Matthew L. S. Beck as Vice President, Investor Relations. He joins CureVac from Solebury Trout, a leading investor relations firm focused on companies in the life sciences and other industries.
"We're excited to welcome Matt to the CureVac team," said Pierre Kemula, Chief Financial Officer, CureVac AG. "His experience advising senior management at numerous life sciences companies, and knowledge of the capital markets in the U.S., will be critical as we advance our business and clinical pipeline of mRNA-based therapies.”
Mr. Beck has more than 18 years of experience in the field of investor relations. Prior to serving as Senior Vice President at Solebury Trout, he was Senior Specialist at NASDAQ OMX’s Corporate Advisory division. Prior to NASDAQ OMX, he served as a Marketing Associate at Dunbar Capital, a fund of hedge funds. Prior to that, he was a Vice President in Goldman Sachs’ NYSE DMM division. Early in his career, Mr. Beck served in increasingly responsible roles at Thomson Financial. He earned a Bachelor of Arts degree in Political Science from Vassar College.
About CureVac AG
CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 18 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies.
To date, CureVac has received approximately $420 million (€400 million) in equity investments including significant investments from SAP founder Dietmar Hopp’s Dievini and an investment of $52 million from the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, Arcturus Therapeutics, Acuitas, and the Bill & Melinda Gates Foundation.
For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.
Media Contacts
Verena Lauterbach, Senior Manager Communications
CureVac AG, Tübingen, Germany
T: +49 7071 9883 1756
verena.lauterbach@curevac.com
Rich Allan
Solebury Trout, New York
T: +1 646 348-2958
rallan@troutgroup.com
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ead87eff-93b5-4710-9115-a394a4b85cd1